Markus Puhlmann

Markus Puhlmann, MD MBA, is a clinical researcher with over 20 years of experience in oncology drug development in solid and liquid tumor indications involving all phases of clinical development.

Before joining Viewpoint, Dr. Puhlmann served as the CD30 Franchise Head of Global Clinical Development at cancer therapy company, Seagen. Prior to his time at Seagen, Dr. Puhlmann worked as Section Head at Merck & Co where he built an extensive trial portfolio to establish pembrolizumab in the GU indications. In this capacity, Dr. Puhlmann led and contributed to many successful regulatory filings for pembrolizumab in various indications for urothelial carcinoma, renal cell cancer and cervical cancer.

Earlier in his career, he held various positions with increasing responsibilities in clinical development and medical affairs at Schering Plough, Bayer and Amgen. Dr. Puhlmann also spent six years at the Surgery Branch, NCI, NIH, where he studied suicide gene therapy approaches including the effects of cytokines on tumor neovasculature.

Dr. Puhlmann trained as a surgeon in the UK and Germany and holds a medical degree from the Ludwig Maximilians University, Munich, Germany and an Executive MBA from Georgetown’s McDonough School of Business.